Selank: A Synthetic Heptapeptide Under Investigation for Anxiolytic and Nootropic Properties in Research Models

Introduction

Selank is a synthetic heptapeptide analogue of tuftsin (Thr-Lys-Pro-Arg), an endogenous immunomodulatory tetrapeptide derived from the Fc region of immunoglobulin G. With the CAS number 129954-34-3 and the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, Selank was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the V.V. Zakusov Institute of Pharmacology. The peptide has been the subject of extensive preclinical and early-stage research for its reported anxiolytic, nootropic, and immunomodulatory properties in experimental models, with a pharmacological profile distinct from classical benzodiazepine-based compounds.

Molecular Structure & Properties

Selank has a molecular formula of C₃₃H₅₇N₁₁O₉ and a molecular weight of approximately 751.88 Daltons. The peptide's stability in biological matrices is enhanced relative to native tuftsin through the addition of the Pro-Gly-Pro C-terminal extension, which confers resistance to enzymatic degradation by prolyl endopeptidase and other peptidases. This structural modification extends the peptide's half-life in experimental systems, enabling more sustained receptor interactions and making it suitable for behavioral and neurochemical research protocols.

Research Findings

Preclinical research in rodent models has characterized Selank's effects across several neurobiological domains. In anxiety-related behavioral paradigms — including the elevated plus maze, open field test, and Vogel conflict test — Selank administration has been associated with reductions in anxiety-like behavior without the sedative or motor-impairing effects typically observed with benzodiazepine compounds [1]. This anxiolytic-like profile, combined with an absence of tolerance development in chronic administration studies, has made Selank a subject of considerable interest in neuropharmacology research.

Investigations into Selank's cognitive effects have demonstrated improvements in learning and memory consolidation in rodent models of stress-induced cognitive impairment, with researchers proposing that these effects may be mediated through modulation of brain-derived neurotrophic factor (BDNF) expression and serotonergic neurotransmission [2]. Studies examining Selank's effects on gene expression in the hippocampus have identified alterations in the expression of genes involved in synaptic plasticity, neurogenesis, and inflammatory signaling [3].

Mechanism of Action (in Experimental Models)

The neurobiological mechanisms underlying Selank's observed effects in experimental models are multifaceted and not yet fully characterized. Current research suggests involvement of several neurotransmitter systems:

GABAergic modulation: Selank has been reported to interact with the GABA-A receptor complex in a manner that potentiates GABAergic inhibitory neurotransmission without direct benzodiazepine receptor binding, potentially explaining its anxiolytic-like properties in behavioral models [4].

Serotonergic effects: Research has documented Selank-associated increases in serotonin (5-HT) turnover in the hippocampus and frontal cortex of rodent models, with corresponding changes in the expression of serotonin transporter (SERT) and 5-HT receptor subtypes [2].

BDNF upregulation: Studies have reported that Selank administration is associated with increased BDNF mRNA expression in hippocampal tissue, suggesting a potential mechanism for its observed effects on synaptic plasticity and cognitive function in experimental models [5].

Enkephalin metabolism: Selank has been shown to inhibit enkephalin-degrading enzymes, including leucine aminopeptidase and angiotensin-converting enzyme, potentially prolonging the activity of endogenous opioid peptides involved in stress regulation [6].

Research Applications

Selank is employed in research contexts focused on anxiety neurobiology, stress-related cognitive impairment, neuroinflammation, and peptide-based modulation of the central nervous system. Its dual anxiolytic and nootropic profile in preclinical models makes it a valuable tool for studies examining the relationship between anxiety, cognition, and neuroplasticity. Researchers have also investigated Selank in models of immune dysregulation, given its structural relationship to tuftsin and reported effects on cytokine expression and natural killer cell activity in experimental settings.

All research involving Selank is conducted for research purposes only within controlled laboratory environments, with the objective of advancing understanding of peptidergic modulation of central nervous system function.

This article is intended for scientific and educational reference within a laboratory research context only. All products sold by Pure Pharm Peptides are for research use only and are not intended for human or animal consumption.

References

1. Semenova, T. P., et al. (2010). Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Doklady Biological Sciences, 431(1), 100–102.
2. Narkevich, V. B., et al. (2008). Effects of the heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/c and C57BL/6 mice: a comparative study. Eksperimental'naia i Klinicheskaia Farmakologiia, 71(5), 8–12.
3. Inozemtseva, L. S., et al. (2016). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biochemistry and Biophysics, 471(1), 386–388.
4. Zozulya, A. A., et al. (2001). Anxiolytic and nootropic activity of selank in models of anxiety and experimental neurosis. Bulletin of Experimental Biology and Medicine, 131(5), 464–466.
5. Kozlovskaya, M. M., et al. (2002). Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova, 88(4), 452–461.
6. Kost, N. V., et al. (2001). Selank inhibits enkephalin-degrading enzymes in human serum. Bulletin of Experimental Biology and Medicine, 131(4), 362–364.